These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9618895)

  • 1. [Coronary mortality lowered by 24%. Convincing results of the LIPID Study on Secondary Prevention].
    Z Kardiol; 1998 Apr; 87(4 Suppl Uberzeugen):1-3. PubMed ID: 9618895
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholesterol reduction and coronary prevention.
    Prabhakaran D
    Natl Med J India; 1997; 10(1):24-5. PubMed ID: 9069704
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of pravastatin on coronary events after myocardial infarction.
    Hazzard WR; Ettinger WH
    N Engl J Med; 1997 Mar; 336(13):961; author reply 962. PubMed ID: 9072700
    [No Abstract]   [Full Text] [Related]  

  • 4. Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?
    Maron DJ
    Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):18-9. PubMed ID: 16265253
    [No Abstract]   [Full Text] [Related]  

  • 5. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of mortality from coronary heart disease with pravastatin.
    Tonkin AM; Ryan EW
    Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention of coronary artery disease.
    Domanski MJ
    N Engl J Med; 2007 Oct; 357(15):1543-5. PubMed ID: 17928603
    [No Abstract]   [Full Text] [Related]  

  • 8. [Primary and secondary prevention of coronary disease by statins].
    Ferrières J
    Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of atherosclerosis with aggressive lipid lowering.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania PC;
    Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pravastatin and coronary heart disease.
    Assmann G; Schulte H; Cullen P
    Circulation; 1998 Dec 22-29; 98(25):2933-4. PubMed ID: 9860800
    [No Abstract]   [Full Text] [Related]  

  • 16. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
    Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
    Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention. Who should take cholesterol-lowering drugs?
    Harv Health Lett; 1998 Jan; 23(3):1-3. PubMed ID: 9650517
    [No Abstract]   [Full Text] [Related]  

  • 18. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of coronary heart disease with pravastatin.
    Samani NJ; de Bono DP
    N Engl J Med; 1996 May; 334(20):1333-4; author reply 1334-5. PubMed ID: 8609957
    [No Abstract]   [Full Text] [Related]  

  • 20. Results of recent trials on the progression of coronary artery disease and recurrent ischemic events: implications for interventional cardiology.
    Pitt B
    J Interv Cardiol; 1994 Dec; 7(6):515-8. PubMed ID: 10155198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.